Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xisomab 3G3 in ESRD patients on hemodialysis
NCT03612856Phase 2Completed
- Sponsor
- Aronora, Inc.
- Start
- Oct 2018
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Xisomab 3G3 in thrombosis (3 arms), sponsored by Aronora, Inc. Primary endpoints: Treatment-related Adverse Events at 21 days, Incidence of Bleeding at the HD Vascular Access Site at Day 5 and 2 more. Started Oct 2018; status: completed.
02
Drugs
Xisomab 3G3
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03612856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03612856.